Details for Patent: 10,960,009

Which drugs does patent 10,960,009 protect, and when does it expire?

Patent 10,960,009 protects CAPLYTA and is included in one NDA.

This patent has forty-five patent family members in sixteen countries.

Summary for Patent: 10,960,009

Title:	Methods of treating schizophrenia and depression
Abstract:	The disclosure provides the use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals for the treatment of residual symptoms of psychosis or schizophrenia. The disclosure also provides novel long acting injectable formulations of particular substituted heterocycle fused gamma-carboline compounds and use of such long acting injectable formulations for the treatment of residual symptoms of psychosis or schizophrenia.
Inventor(s):	Vanover; Kimberly (New York, NY), Li; Peng (New Milford, NJ), Mates; Sharon (New York, NY), Davis; Robert (San Diego, CA), Wennogle; Lawrence P. (Hillsborough, NJ)
Assignee:	INTRA-CELLULAR THERAPIES, INC. (New York, NY)
Application Number:	16/392,409
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 10,960,009

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Intra-cellular	CAPLYTA	lumateperone tosylate	CAPSULE;ORAL	209500-001	Dec 20, 2019		RX	Yes	Yes						TREATMENT OF SCHIZOPHRENIA

International Family Members for US Patent 10,960,009

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2014360452
Australia	2019200301
Australia	2020202386
Australia	2021290277
Brazil	112016012781
Canada	2932610
Canada	3148303